aspirin has been researched along with Sicca Syndrome in 12 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, the goal of this paper was to create a physiologically based pharmacokinetic (PBPK) model to offer a reasonable starting point for required total AT-RvD1 dosage to be administered in future mice and humans thereby eliminating the need for excessive use of animals and humans in preclinical and clinical trials, respectively." | 5.56 | Predictive modeling of aspirin-triggered resolvin D1 pharmacokinetics for the study of Sjögren's syndrome. ( Baker, OJ; Yellepeddi, VK, 2020) |
| " The goal of this study was to determine whether systemic preventive treatment with Aspirin-triggered RvD1 (AT-RvD1) reduces inflammation and preserves secretory functioning in NOD/ShiLtJ SS-like mice." | 3.85 | AT-RvD1 Promotes Resolution of Inflammation in NOD/ShiLtJ mice. ( Baker, OJ; Easley, JT; Maruyama, CL; Trump, BG; Wang, CS, 2017) |
| "Primary biliary cirrhosis is a disease of the small bile ducts with altered immunologic responsiveness often associated with various collagen diseases." | 2.36 | Primary biliary cirrhosis as a collagen disease. ( Schaffner, F, 1979) |
| "Treatment with hydroxychloroquine might not be enough to lower the cardiovascular risk significantly in diabetes patients with Sjögren syndrome." | 1.72 | Sjögren syndrome is a hidden contributor of macrovascular and microvascular complications in patients with type 2 diabetes. ( Leong, PY; Su, YJ; Wang, YH; Wei, JC, 2022) |
| " Therefore, the goal of this paper was to create a physiologically based pharmacokinetic (PBPK) model to offer a reasonable starting point for required total AT-RvD1 dosage to be administered in future mice and humans thereby eliminating the need for excessive use of animals and humans in preclinical and clinical trials, respectively." | 1.56 | Predictive modeling of aspirin-triggered resolvin D1 pharmacokinetics for the study of Sjögren's syndrome. ( Baker, OJ; Yellepeddi, VK, 2020) |
| " Therefore, we investigated whether the more stable aspirin-triggered (AT) epimer, AT-RvD1, combined with reduced doses of DEX is effective in treating TNF-α-mediated disruption of polarized rat parotid gland (Par-C10) epithelial cell clusters." | 1.43 | AT-RvD1 combined with DEX is highly effective in treating TNF-α-mediated disruption of the salivary gland epithelium. ( Baker, OJ; Easley, JT; Maruyama, CL; Wang, CS, 2016) |
| "A diagnosis of mixed connective tissue disease (Sharp-syndrome) was established." | 1.30 | [A patient with mixed collagen disease, antiphospholipid syndrome and Sjögren syndrome]. ( Hartmann, F; Kranzhöfer, N; Lindemuth, R; Zuber, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (33.33) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Su, YJ | 1 |
| Leong, PY | 1 |
| Wang, YH | 1 |
| Wei, JC | 1 |
| Dos Santos, HT | 1 |
| Nam, K | 2 |
| Gil, D | 1 |
| Yellepeddi, V | 1 |
| Baker, OJ | 5 |
| Yellepeddi, VK | 1 |
| Wang, CS | 3 |
| Maruyama, CL | 3 |
| Easley, JT | 2 |
| Trump, BG | 2 |
| Placais, L | 1 |
| Carrat, F | 1 |
| Carbillon, L | 1 |
| Nicaise Roland, P | 1 |
| Benbara, A | 1 |
| Cacciatore, C | 1 |
| Fain, O | 1 |
| Mekinian, A | 1 |
| Dean, S | 1 |
| Barrow, MV | 1 |
| Quick, DT | 1 |
| Cunningham, RW | 1 |
| McKendry, RJ | 1 |
| Zuber, M | 1 |
| Kranzhöfer, N | 1 |
| Lindemuth, R | 1 |
| Hartmann, F | 1 |
| Schaffner, F | 1 |
| Tiger, LH | 1 |
| Gordon, MH | 1 |
| Ehrlich, GE | 1 |
| Shapiro, B | 1 |
2 reviews available for aspirin and Sicca Syndrome
| Article | Year |
|---|---|
Current experimental methods to investigate the impact of specialized pro-resolving lipid mediators on Sjögren's syndrome.
Topics: Aspirin; Humans; Inflammation; Lipids; Salivary Glands; Sjogren's Syndrome | 2022 |
Primary biliary cirrhosis as a collagen disease.
Topics: Adrenal Cortex Hormones; Antibodies; Antigen-Antibody Complex; Aspirin; Collagen Diseases; Complemen | 1979 |
10 other studies available for aspirin and Sicca Syndrome
| Article | Year |
|---|---|
Sjögren syndrome is a hidden contributor of macrovascular and microvascular complications in patients with type 2 diabetes.
Topics: Aspirin; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hydroxychlo | 2022 |
Predictive modeling of aspirin-triggered resolvin D1 pharmacokinetics for the study of Sjögren's syndrome.
Topics: Administration, Intravenous; Animals; Aspirin; Clinical Trials as Topic; Computer Simulation; Diseas | 2020 |
AT-RvD1 Promotes Resolution of Inflammation in NOD/ShiLtJ mice.
Topics: Animals; Aspirin; Dexamethasone; Docosahexaenoic Acids; Epithelium; Female; Inflammation; Male; Mice | 2017 |
Obstetrical morbidity related to anti-SSA antibodies: Data from a French monocentric retrospective study.
Topics: Adult; Antibodies, Antinuclear; Antiphospholipid Syndrome; Aspirin; Databases, Factual; Female; Fran | 2019 |
Aspirin Triggered Resolvin D1 reduces inflammation and restores saliva secretion in a Sjögren's syndrome mouse model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cytokines; Disease Models, Animal; Docosa | 2019 |
AT-RvD1 combined with DEX is highly effective in treating TNF-α-mediated disruption of the salivary gland epithelium.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Combined Modality Therapy; Dexamethasone; | 2016 |
Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.
Topics: Arthritis, Rheumatoid; Aspirin; Female; Hemorrhagic Disorders; Humans; Hypoprothrombinemias; Liver D | 1967 |
Treatment of Sjogren's syndrome with essential fatty acids, pyridoxine and vitamin C.
Topics: Ascorbic Acid; Aspartate Aminotransferases; Aspirin; Fatty Acids, Essential; Female; Humans; Indomet | 1982 |
[A patient with mixed collagen disease, antiphospholipid syndrome and Sjögren syndrome].
Topics: Adult; Antiphospholipid Syndrome; Aspirin; Azathioprine; Biopsy; Diagnosis, Differential; Drug Thera | 1998 |
Liver enlargement demonstrated by scintigraphy in rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Female; Gold Sodium Thiomalate; Hepatomegaly; Humans; L | 1976 |